Glycogen synthase kinase-3 and cancer: good cop, bad cop?

Cancer Cell. 2008 Nov 4;14(5):351-3. doi: 10.1016/j.ccr.2008.10.013.

Abstract

Dogma held that inhibition of the pleiotropic protein kinase glycogen synthase kinase-3 (GSK-3) was procarcinogenic due to its natural repression of beta-catenin. Now, Wang et al. have found the reverse in certain leukemias, possibly paving the way for small-molecule GSK-3 inhibitors as selective anticancer agents.

MeSH terms

  • Enzyme Inhibitors / therapeutic use*
  • Gene Expression Regulation / drug effects*
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors*
  • Glycogen Synthase Kinase 3 / genetics
  • Glycogen Synthase Kinase 3 / metabolism*
  • Humans
  • Leukemia / drug therapy*
  • Leukemia / metabolism
  • Leukemia / pathology
  • Signal Transduction / drug effects
  • beta Catenin / metabolism

Substances

  • Enzyme Inhibitors
  • beta Catenin
  • Glycogen Synthase Kinase 3